Literature DB >> 17045649

T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

Ahmed Aribi1, Yang Huh, Michael Keating, Susan O'brien, Alessandra Ferrajoli, Stefan Faderl, William Wierda, Hagop Kantarjian, Farhad Ravandi.   

Abstract

T-cell large granular lymphocytic (T-LGL) leukemia is characterized by cytopenia and clonal proliferation of large granular lymphocytes. We identified 26 patients with T-LGL leukemia seen at our institution over a period of 8 years. The majority of the patients were asymptomatic at diagnosis. Nine patients were treated with cyclosporine; one achieved a complete remission, and four had a hematological response. Other treatment modalities included single agent alemtuzumab, alemtuzumab combined with pentostatin, fludarabine, and combination of fludarabine and cyclophosphamide. Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045649     DOI: 10.1016/j.leukres.2006.09.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

Review 1.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

2.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

3.  Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases.

Authors:  Benoît Bareau; Jérôme Rey; Mohamed Hamidou; Jean Donadieu; Jeff Morcet; Oumedaly Reman; Nicolas Schleinitz; Olivier Tournilhac; Mikael Roussel; Thierry Fest; Thierry Lamy
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

4.  T-cell large granular lymphocytic leukemia: 4 cases.

Authors:  Anila Rashid; Mohammad Khurshid; Arsalan Ahmed
Journal:  Blood Res       Date:  2014-09-25

Review 5.  Large granular lymphocytic leukemia: a brief review.

Authors:  Ekta Rahul; Aparna Ningombam; Shreyam Acharya; Pranay Tanwar; Amar Ranjan; Anita Chopra
Journal:  Am J Blood Res       Date:  2022-02-15

6.  Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.

Authors:  Sanjay R Mohan; Michael J Clemente; Manuel Afable; Heather N Cazzolli; Nelli Bejanyan; Marcin W Wlodarski; Alan E Lichtin; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

7.  T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.

Authors:  Aleksandra Sretenovic; Darko Antic; Snezana Jankovic; Mirjana Gotic; Maja Perunicic-Jovanovic; Ljubomir Jakovic; Biljana Mihaljevic
Journal:  Med Oncol       Date:  2009-03-21       Impact factor: 3.064

8.  T-cell large granular lymphocytic leukemia: treatment experience with fludarabine.

Authors:  Renata Oliveira Costa; Marcelo Bellesso; Dalton Alencar Fischer Chamone; Milton Artur Ruiz; Abrahão Elias Hallack Neto; Vera Lucia Aldred; Juliana Pereira
Journal:  Clinics (Sao Paulo)       Date:  2012-07       Impact factor: 2.365

9.  Atiprimod triggered apoptotic cell death via acting on PERK/eIF2α/ATF4/CHOP and STAT3/NF-ΚB axis in MDA-MB-231 and MDA-MB-468 breast cancer cells.

Authors:  Ajda Coker-Gurkan; Esin Can; Semanur Sahin; Pınar Obakan-Yerlikaya; Elif-Damla Arisan
Journal:  Mol Biol Rep       Date:  2021-07-09       Impact factor: 2.316

10.  Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.

Authors:  Bogdan Dumitriu; Sawa Ito; Xingmin Feng; Nicole Stephens; Muharrem Yunce; Sachiko Kajigaya; Joseph J Melenhorst; Olga Rios; Priscila Scheinberg; Fariba Chinian; Keyvan Keyvanfar; Minoo Battiwalla; Colin O Wu; Irina Maric; Liqiang Xi; Mark Raffeld; Pawel Muranski; Danielle M Townsley; Neal S Young; Austin J Barrett; Phillip Scheinberg
Journal:  Lancet Haematol       Date:  2015-12-17       Impact factor: 18.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.